Resources – Adragos Pharma https://adragos-pharma.com Your Global CDMO Thu, 11 Dec 2025 12:01:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.3 https://adragos-pharma.com/wp-content/uploads/2024/04/cropped-Adragos-Pharma-Symbol-2024-32x32.png Resources – Adragos Pharma https://adragos-pharma.com 32 32 Fast-tracking clinical success with the right Fill & Finish CDMO – Oncology case study https://adragos-pharma.com/fast-tracking-clinical-success-with-the-right-fill-finish-cdmo-oncology-case-study/ https://adragos-pharma.com/fast-tracking-clinical-success-with-the-right-fill-finish-cdmo-oncology-case-study/#respond Wed, 15 Oct 2025 13:56:15 +0000 https://adragos-pharma.com/?p=22760

Based on a case study presented in our webinar “Fast tracking clinical success: right Fill & Finish CDMO” by Marie-Sophie Quittet, PharmD, PhD (Head of Strategic Projects, Adragos Jura)

When a small-batch oncology product went off the market for several years due to repeated CMO disruptions, Adragos Jura re-initiated compliant supply across multiple markets with minimal dossier changes and maximum yield from scarce bulk. This concise case study shows how pairing regulatory rigor with agile problem-solving accelerated timelines for a product serving a small patient population.

Discover how our team navigated today’s toughest fill & finish challenges: aligning legacy processes to current expectations (including PUPSIT), preserving limited bulk volume, validating custom stopper machinability and closure integrity, planning for a >90-hour lyophilization cycle, implementing robust QA and traceability for blood-derived materials, dual-sourcing sterilizing filters during pandemic-era shortages, and simplifying VAT through inward processing with transparent API consumption tracking.

You will see the practical steps that made the difference: rigorous gap assessment and APS alignment, targeted lab development to set a precise post-filtration discard volume, smart campaign planning, and close sponsor–QA collaboration for a smooth variation submission and inspection. The result: accelerated implementation, preserved bulk, dossier stability, resilient supply, and an ongoing partnership that continues to address new analytical needs with confidence.

Download the case study now:

Get the PDF to learn the framework, decisions, and data that helped restart a complex small-batch oncology product fast and compliantly. Includes a practical checklist of questions to ask a Fill & Finish CDMO before selecting them.

]]>
https://adragos-pharma.com/fast-tracking-clinical-success-with-the-right-fill-finish-cdmo-oncology-case-study/feed/ 0
How to Effectively Develop Value-Added Medicines [Webinar] https://adragos-pharma.com/value-added-medicines-from-development-to-approval-webinar/ https://adragos-pharma.com/value-added-medicines-from-development-to-approval-webinar/#respond Wed, 01 Oct 2025 08:51:11 +0000 https://adragos-pharma.com/?p=12408 In the rapidly evolving pharmaceutical landscape, value-added medicines (VAMs) are emerging as pivotal solutions that optimize patient outcomes and health care efficiency. These innovative products, which include reformulated, repurposed, or combined therapies, enhance existing medications’ efficacy, safety, and convenience.

This webinar will include examples of successful developments of value-added medicines in Europe, aiming to provide an in-depth exploration of the key regulatory and development aspects of value-added medicines, with a focus on the European context.

What You Will Learn

1. Regulatory Frameworks And Pathways In Europe

· Understanding the European regulatory environment for VAMs.
Navigating regulatory challenges and opportunities.
· Case studies illustrating successful regulatory strategies and approvals within Europe.

2. Development Strategies

· Key considerations in the development of VAMs, including formulation science, clinical trial design, and patient-centric approaches.
· Innovations in drug delivery systems and their impact on the development process.

Our Key Speakers

We are honored to welcome our expert speakers, leaders in healthcare and pharmaceutical innovation, who will share insights on the transformative impact of Value-Added Medicines.

Discover More About Value-Added Medicines

Dive into the world of Value Added Medicines (VAM) and gain valuable insights and knowledge about these transformative healthcare solutions.

Value Added Medicines (VAM): Everything You Need To Know

Let’s dive into what Value Added Medicines (VAM) really means, its incredible benefits, the challenges it faces, and how it’s navigating the complex world of regulations.

infographic about 505b2

Exploring 505b2 Value-Added Medicines: A Complete Overview

This article delves into the 505(b)(2) pathway, its benefits, and its critical role in drug development, showing pharmaceutical companies how to optimize their strategies.

]]>
https://adragos-pharma.com/value-added-medicines-from-development-to-approval-webinar/feed/ 0
MAH Transfers in Japan & Smooth Market Entry [Case Study] https://adragos-pharma.com/mah-transfers-in-japan-smooth-market-entry-case-study/ https://adragos-pharma.com/mah-transfers-in-japan-smooth-market-entry-case-study/#respond Wed, 03 Sep 2025 12:55:17 +0000 https://adragos-pharma.com/?p=22302 In the Japanese pharmaceutical market, a Marketing Authorization Holder (MAH) is legally required to commercialize pharmaceutical products. However, companies often face different regulatory and logistical situations regarding their MAH status. This chapter outlines two specific MAH transfer scenarios and demonstrates how Adragos Pharma can support companies in both cases.

MAH Transfer – MAH Available in Japan

In this scenario, Company A is a European-based pharmaceutical company with both its headquarters and manufacturing sites located in Europe. It already has an established MAH entity in Japan, which allows it to market and distribute products domestically. At some point, Company A decides to transfer its MAH responsibilities to Company B, which is headquartered in the United States. Like Company A, Company B also has a manufacturing site in Europe and a registered MAH entity in Japan.

MAH Available in Japan

Because both companies have MAH status in Japan and the manufacturing sites remain unchanged including those responsible for filling, visual inspection, and packaging in Europe the transfer process is relatively straightforward. No adjustments to the Japanese supply chain or manufacturing operations are needed.
As a result, the timeline for launching the product after initiating the MAH transfer can be significantly shortened. Typically, the transition from the date of the MAH transfer signature to the release of the product can be completed within approximately ten months.
Adragos Pharma plays a central role during this transition. All contractual discussions, including those related to packaging and supply chain, are conducted in English removing the need for Japanese translation and allowing for more efficient communication. Additionally, during the transition period, special solutions such as a dual-barcode system can be introduced.
This allows packaging materials to display both the previous and new MAH information, which is especially useful if there is existing stock of bulk materials. These coordinated efforts ensure a smooth and compliant transition with minimal impact on timelines or supply continuity.

MAH Transfer timeline

MAH Transfer – MAH Not Available in Japan

A different scenario occurs when the company intending to become the MAH has not yet established a legal MAH entity in Japan. In this case, Company A is again headquartered in Europe and wishes to market its product in Japan but lacks the necessary local MAH status. To address this, it partners with Company B, a UK-based firm that is already registered as an MAH in Japan.

MAH not available in Japan

Under this arrangement, Company A remains the main point of contact for all commercial matters, such as purchase orders and invoicing. Meanwhile, Company B, as the registered MAH, is responsible for handling technical, regulatory, quality, and supply related activities within Japan. Adragos Pharma facilitates communication and coordination between both companies, ensuring alignment across all aspects of the transfer and market preparation.
In many cases, three-party meetings are conducted to address the complexities of the handover and establish clear responsibilities. This collaborative approach enables Company A to enter the Japanese market without needing to set up its own MAH entity, significantly reducing the time and investment typically required for market entry.
Moreover, if Company A has not yet identified a suitable MAH partner like Company B, Adragos Pharma can support the search by introducing qualified candidates who meet regulatory requirements and can act as the MAH on Company A’s behalf.
Through expert project management, multilingual communication support, and regulatory insight, Adragos Pharma ensures that companies regardless of their MAH status in Japan can successfully transfer marketing authorization and bring their products to the Japanese market efficiently and compliantly.

]]>
https://adragos-pharma.com/mah-transfers-in-japan-smooth-market-entry-case-study/feed/ 0
Clinical Success in Vaccine Development with Adragos [Case Study] https://adragos-pharma.com/clinical-success-in-vaccine-development-with-adragos/ https://adragos-pharma.com/clinical-success-in-vaccine-development-with-adragos/#respond Wed, 04 Jun 2025 08:53:02 +0000 https://adragos-pharma.com/?p=17871 Discover how a US-based vaccine developer reached Phase 3 clinical trials in just 4 years by partnering with Adragos Pharma. Learn how we can help you overcome complex Fill & Finish manufacturing challenges and accelerate your path to approval.

What you will discover

This case study reveals the journey of overcoming complex manufacturing and analytical challenges, and provides actionable insights on how to:

  • Managing over 30 unique Active Pharmaceutical Ingredients (APIs) with full traceability and compliance.
  • Implementing customized documentation and rigorous aseptic processing.
  • Establishing analytical protocols aligned with USP and EP standards.
  • Achieving maximum production efficiency while maintaining uncompromising quality.

See how our flexibility in planning, dedicated operator training, and ongoing process optimization enabled swift progression through clinical phases, ultimately supporting innovation and safety in vaccine development.

Ready to learn more?

Download the full case study now and gain actionable insights to drive your next clinical manufacturing success.

]]>
https://adragos-pharma.com/clinical-success-in-vaccine-development-with-adragos/feed/ 0
Shiro’s Adventure: Exploring the Essence of Our Company [Manga] https://adragos-pharma.com/shiro-adventure-exploring-the-essence-of-our-company-manga/ https://adragos-pharma.com/shiro-adventure-exploring-the-essence-of-our-company-manga/#respond Tue, 03 Jun 2025 13:35:35 +0000 https://adragos-pharma.com/?p=17902

Discover our story through the eyes of Shiro, our Chief Happiness Officer! Join Shiro as he guides you on a journey through our company’s origins, core values, and the dedicated people who drive our mission forward. Each episode shines a spotlight on a unique aspect of our company, offering you an inside look at what makes us who we are.

Meet the Manga Cast

Shiro
Chief Happiness Officer
Dr. Andreas Raabe
Chief Executive Officer
Henny Zijlstra
Chief Commercial Officer
Norbert Kuebler
Chief Scientific Officer
Daniel Wigbers
Chief Financial & Digital Officer
Marco Gorgas
Chief Operations Officer

Manga Episodes

Episode #1: Shiro the Hero

In this special manga series, we follow Shiro, the beloved dog of our CEO, on his journey to becoming our official Chief Happiness Officer. In the very first episode, Shiro saves the day with his unique instincts, infectious energy, and undeniable charm. His actions not only win the hearts of the dedicated C-level team, they also earn him an official place on the team and the important title of CHO. “Shiro the Hero” is all about how Shiro joins the company, proving that sometimes, a little heart (and a wagging tail) can make all the difference.

Episode #2 Shiro to the Rescue at Interphex! 

At Interphex in Tokyo, our CCO, Henny suddenly realizes her crucial presentation notes are missing after a jet-lagged journey from Barcelona and panics as the start time looms. Hide hatches a bold plan: have Shiro, the ever-enthusiastic office dog, sprint through the park to dodge traffic and retrieve the folder in time. With the clock ticking and everyone on edge, it is a race against time to see if Shiro can pull off this daring delivery.

]]>
https://adragos-pharma.com/shiro-adventure-exploring-the-essence-of-our-company-manga/feed/ 0
How a European Biopharma Entered Japan [Case Study] https://adragos-pharma.com/case-study-how-a-european-biopharma-entered-japan/ https://adragos-pharma.com/case-study-how-a-european-biopharma-entered-japan/#respond Tue, 27 May 2025 15:14:45 +0000 https://adragos-pharma.com/?p=17849 How a Seamless Marketing Authorization Transfer Enabled a Swift Biopharma Launch in Japan

When it comes to bringing high-value biopharmaceuticals to new markets, meticulous planning and flawless execution are essential. This is especially true for products as complex as monoclonal antibodies, which require stringent controls and regulatory precision. Recently, Adragos Pharma orchestrated a smooth transfer and commercial launch of such a product—a monoclonal antibody in pre-filled syringes and auto-injectors—for a European pharma company entering the Japanese market.

Strategizing Global Supply: Keeping Manufacturing at Home

The European biotechnology company made a strategic decision to continue aseptic drug product filling at its manufacturing site in Europe. This approach leveraged the site’s capabilities and ensured consistency in production quality. The challenge, however, was to manage the importation and final packaging operations in Japan, where strict regulatory requirements and logistical considerations come into play.

Tapping into Local Expertise: Adragos Pharma’s Kawagoe Facility

To bridge the gap between continents, Adragos facilitated the import of bulk drug product into Japan. The Kawagoe facility became the hub for crucial final steps: visual inspection, secondary packaging, and stringent quality control testing. Only after successfully clearing these stages was the finished product released to the Marketing Authorization Holder (MAH), setting the stage for distribution to wholesalers and, eventually, to patients throughout Japan.

Mapping the Regulatory Journey: From J-NDA to Launch

Navigating Japan’s regulatory landscape requires expertise and careful timeline management. Here’s how Adragos and its client made it happen:

  • Month 0: Submission of the Japanese New Drug Application (J-NDA) kicked off the regulatory process.
  • Months 1–12: Intensive regulatory and technical activities took place. The teams prepared and submitted the GMP Pre-Approval Inspection (PAI) application, completed essential process qualification (PQ) for packaging, and finalized development of the packaging process itself.
  • Analytical Methods Transfer: Concurrently, analytical methods were successfully transferred from the client’s European site to the Adragos facility in Japan, ensuring consistency and compliance with local requirements.
  • Month 12: With regulatory approval secured, the first commercial batch of bulk product was shipped to Japan, ready for final inspection, packaging, and delivery.

14 Months from Submission to Market Entry: From the J-NDA filing to the commercial launch, the entire process was completed in approximately 14 months—a rapid and efficient turnaround for a sophisticated biopharmaceutical product.

Case_Study_BioProduct
BioProduct Case Study

The Outcome: High-Impact Launch, High-Quality Care

By combining global manufacturing strengths with localized regulatory and packaging expertise, the project exemplified how biopharma companies can efficiently bring innovative medicines to new markets—without compromising on quality or compliance. End result: patients in Japan gained timely access to a life-changing monoclonal antibody therapy, and the European company successfully expanded its global footprint.

Key Takeaway

Cross-border pharmaceutical launches require not only technical and regulatory know-how, but also seamless coordination across continents. The successful launch of this monoclonal antibody in Japan demonstrates how smart partnerships and optimized processes can accelerate access to breakthrough therapeutics worldwide.

]]>
https://adragos-pharma.com/case-study-how-a-european-biopharma-entered-japan/feed/ 0
Entering Japan: Guide to Pharma Compliance & Market Access [E-Book] https://adragos-pharma.com/entering-japan-guide-to-pharma-compliance-market-access-e-book/ https://adragos-pharma.com/entering-japan-guide-to-pharma-compliance-market-access-e-book/#respond Mon, 26 May 2025 15:02:08 +0000 https://adragos-pharma.com/?p=17829 This e-book, “Entering Japan: A Practical Guide to Pharmaceutical Compliance and Market Access”, provides a comprehensive and practical overview for pharmaceutical companies aiming to enter the Japanese market. It explains the regulatory, logistical, and compliance challenges involved and presents step-by-step guidance on navigating Japan’s complex pharmaceutical environment.

Key topics:

  • General Information about Japan: Discover what makes Japan a strategic choice. From its aging population to a world-class healthcare system driving pharmaceutical demand.
  • Requirements for the Japanese Pharmaceutical Market: Navigating into the Japan’s Pharmaceutical Regulations: MHLW, PMDA, MAH.
  • How To Enter The Japanese Market: Understand what you need to do to meet the highest Japanese quality standards.
  • Case Studies: Real-world examples demonstrate different scenarios, such as how a European biopharmaceutical company successfully launched in Japan and how Marketing Authorization Holder (MAH) transfers are practically managed between international companies with Japanese subsidiaries.

Overall, the guide serves as a practical reference for foreign pharmaceutical companies, offering actionable strategies and best practices to ensure successful compliance and market access in Japan.

Download the e-book now to learn how we can help you and facilitate the entrance to the Japanese market 👇

]]>
https://adragos-pharma.com/entering-japan-guide-to-pharma-compliance-market-access-e-book/feed/ 0
Inside Adragos Pharma: The People Behind the Vision [Podcast] https://adragos-pharma.com/inside-adragos-pharma-our-podcast/ https://adragos-pharma.com/inside-adragos-pharma-our-podcast/#respond Tue, 20 May 2025 15:39:46 +0000 https://adragos-pharma.com/?p=17667 About the Podcast

The People Behind the Vision takes you beyond the headlines and into the heart of the pharmaceutical industry. Each episode reveals the personal journeys, insights, and expertise of the remarkable individuals behind the scenes at Adragos. In an industry often defined by scientific papers and clinical results, we believe the human stories deserve to be told.

Hosted by Lydia Marinou, our podcast connects you with industry veterans who share their:

  • Leadership philosophies and strategies that drive organizational success
  • Career paths and pivotal moments that shaped their professional journeys
  • Perspectives on industry challenges and how they navigate complexity
  • Visions for the future of pharma and healthcare innovation
  • Personal motivations that fuel their dedication to improving patient lives

Whether you are a pharmaceutical professional, healthcare partner, or simply curious about the people shaping modern medicine, these conversations offer valuable perspectives on leadership, innovation, and purpose-driven work in the pharmaceutical landscape.

Meet Your Host

For a more comprehensive look into Lydia’s journey, connect with her on Linkedin.

Lydia, brings both scientific expertise and business insights to her role as host of our podcast. With a doctorate in Biomedical Engineering and experience in biomaterials innovation, she bridges the technical and commercial worlds of pharmaceuticals. After transitioning from academia to industry, Lydia now serves as a Business Development Associate at Adragos Pharma, where she identifies growth opportunities and supports commercial initiatives.

In each episode, Lydia creates a relaxed yet insightful atmosphere where guests can share their stories. Her combined scientific background and business perspective allow her to dive deep into technical discussions while making them accessible to all listeners. Whether chatting with laboratory scientists, corporate executives, or industry pioneers, Lydia’s curiosity bring out the human side of Adragos. Join her as she uncovers the passion, challenges, and personal journeys of the people shaping Adragos Pharma.

Featured Episodes

bastian and Lydia Podcast cover

Embracing Change: Conversations with our Team

 In this episode, we welcome Bastian, Global Head of Digitalization & IT to talk his journey that lead to Adragos, and embracing change as we enter the new digital era of AI. Bastian shares his favorite tips and tricks for using AI tools effectively, offers practical advice on finding your own super power at work, and dives into strategies for overcoming resistance to digital transformation in pharma.

As someone born and raised in Munich, Bastian also reveals his personal recommendations for experiencing the city like a local.

Whether you are interested in the future of pharma, digital innovation, or just want some insider tips for Munich, this episode has something for you! 

Nicole and Lydia cover podcast
2 cartoon women

Culture, Ambition, and Balance: Conversations with our Team

In this episode, we welcome Nicole, our dynamic Business Development Manager in Barcelona, to share her unique story and perspective.

Join host Lydia Marinou as she sits down with Nicole to explore the contrasts and connections between Chinese and European business cultures. Nicole opens up about balancing her personal interests, building a family abroad, and shaping a professional journey that spans continents. She dives into how her Chinese upbringing and values have influenced her work ethic, resilience, and approach to growth, both at work and in life.

]]>
https://adragos-pharma.com/inside-adragos-pharma-our-podcast/feed/ 0
Fast tracking clinical success: right Fill & Finish CDMO [Webinar] https://adragos-pharma.com/fast-tracking-clinical-success-right-fill-finish-cdmo-webinar/ https://adragos-pharma.com/fast-tracking-clinical-success-right-fill-finish-cdmo-webinar/#respond Mon, 17 Mar 2025 16:51:22 +0000 https://adragos-pharma.com/?p=16347 Selecting the right Fill & Finish CDMO can make or break a product’s commercial success. In this webinar, join industry experts to explore key strategies for navigating this crucial stage, ensuring optimal efficiency where it matters most.

Key Learning Points

✅Learn essential criteria for choosing a Fill & Finish CDMO, focusing on technology, compliance and scalability to align with your development goals

✅Explore strategies to streamline Fill & Finish processes, enhancing efficiency and reducing product launch timelines

✅Understand evolving industry trends and identify challenges and opportunities in the Fill & Finish sector.

Agenda:

Understanding the Role of CDMOs in Fill and Finish​

  • Importance of CDMOs for F&F
  • When to start involving a F&F CDMO? The earlier: the better

Criteria for Selecting a Good CDMO​

  • Highly Specialised Expertise​
  • Risk Management​
  • Regulatory Expertise​
  • Intellectual Property​
  • Speed to Market​
  • Scalability and Flexibility​
  • Cost Transparency

Real Case Studies​

Our Key Speakers

We are honored to welcome our expert speaker, leader pharmaceutical innovation and Clinical Trial Manufacturing, who will share insights on how to chose the correct Fill & Finish CDMO.

Marie-Sophie Quittet, Head of Strategic Projects, Adragos Jura

Marie-Sophie holds both a Doctor of Pharmacy (PharmD) and a Doctor of Philosophy (PhD), showcasing her expertise in the pharmaceutical industry. As Head of Customer Relationship and Strategy Partnership Expert, she has over a decade of experience, spearheading clinical production projects in Europe and the US. Her leadership in implementing clinical and commercial projects highlights her strategic acumen. Beyond her professional life, Marie-Sophie balances her career with being a devoted mother. Her love for human relationships enhances her customer relations role, while reading and cooking provide creative balance. With her wealth of experience and a profound understanding of both the scientific and interpersonal aspects of the pharmaceutical industry, Marie-Sophie continues to make significant contributions, fostering innovation and collaboration within her field.

Discover More About Clinical Manufacturing

The Future of Pharma: Understanding Lyophilisate Technology and Its Applications

One technology that has revolutionized the industry is lyophilisation (freeze-drying), which produces lyophilisates—a highly stable, easy-to-reconstitute dosage form.

Clinical Trials: Essential Insights into Clinical Trial Services for Patients

This comprehensive guide explores various aspects of clinical trials, offering valuable insights for patients and pharmaceutical professionals alike.

]]>
https://adragos-pharma.com/fast-tracking-clinical-success-right-fill-finish-cdmo-webinar/feed/ 0
How To Enter The Japanese Market [Webinar] https://adragos-pharma.com/how-to-enter-the-japanese-market-webinar/ https://adragos-pharma.com/how-to-enter-the-japanese-market-webinar/#respond Wed, 05 Mar 2025 16:39:37 +0000 https://adragos-pharma.com/?p=15843 Expanding into Japan can be complex, but with the right expertise and regulatory knowledge, your products can successfully enter this high-potential market. Join us for an exclusive webinar where we’ll guide you through the essential steps of meeting Japan’s regulations and strict quality requirement.

What’s on the agenda?

  • An overview of Japan’s pharmaceutical market, with a look at why this is such a critical market
  • Key regulatory requirements for entering the Japanese market
  • How to ensure compliance and drive product success
  • What supply chain strategy and processes make most sense for the Japanese market
  • Common challenges and solutions to overcome them
  • Best practices for smooth market entry

… and more!

Our Key Speakers

We are honored to welcome our expert speakers, leaders in healthcare and pharmaceutical innovation, who will share insights on Visual Inspection and Packaging, focusing on regulations, quality, and the secrets to enter the Japan market.

Masako Hirota, Head of Quality Operations

Masako is the Head of Quality Operations. She has more than 15 years of experience in quality management and assurance with multinational pharmaceutical companies in Europe and America. With a Master’s degree in Pharmacy, she deeply understands the differences between Western regulatory requirements and Japanese practices. As the head of the quality department at a foreign-affiliated manufacturing site, she has effectively led efforts to close these gaps, ensuring compliance and operational excellence, and successfully delivering medicine to the Japanese market.

Hideyuki Tanaka, Head of Commercial US & APAC

Hide serves as Adragos’ Head Commercial US & APAC and brings over two decades of experience within the pharmaceutical and CDMO industry. He has an extensive global background spanning the United States, Europe, and Japan. Throughout Hide’s career, he has excelled in roles covering sales, marketing, business development, corporate governance, project management, and medicinal chemistry.  Possessing a Master’s in Pharmaceutical Chemistry and an MBA from Bond University in Australia, Hide exemplifies an unwavering commitment to professional growth.

Discover More About Visual Inspection

Dive into the world of Visual Inspection and gain valuable insights and knowledge about the key actions to enter the Japan market.

Pharma Visual Inspection: What Is It and Why You Need It

Discover the future of pharma visual inspection with our cutting-edge technology and navigate excellence in quality control like never before.

Japan’s Pharma Market Entry Process: An Essential Overview

Master the Japan Pharma Market Entry Process with our detailed overview. Gain a competitive edge and succeed in this dynamic market.

]]>
https://adragos-pharma.com/how-to-enter-the-japanese-market-webinar/feed/ 0